A double-blind, randomised cross-over study to evaluate the absorption of a commercially available Ginkgo biloba extract compared to the liposomal extract Ginkgosome

BMC Complement Med Ther. 2022 Aug 3;22(1):206. doi: 10.1186/s12906-022-03679-x.

Abstract

Background: Ginkgo biloba extracts (GBE) have been used in traditional medicines for centuries. GBE has been shown to deliver protective effects against symptoms of age-related cognitive decline. Despite there being standardised extractions for GBE, there is still variability in the absorption and efficacy of different extracts. Following the development of a liposomal GBE (Ginkgosome™), the aim of this study is to investigate the absorption of the liposomal formulation compared to a comparator formulation of equal dose.

Methods: Thirteen healthy male and female volunteers completed this single equivalent dose, randomised, double-blind crossover study. Plasma concentrations were determined at baseline and at regular intervals over a 24-h period following ingestion of 120 mg of either a liposomal or comparator formulation.

Results: The liposomal formulation was able to increase plasma concentration of ginkgolide B and C by 1.9 and 2.2-fold compared to the comparator formulation.

Conclusion: The novel liposomal formulation is safe in humans and demonstrates superior absorption for the supply of GBE constituents compared to a comparator standardised formulation.

Keywords: Absorption; Ginkgo biloba; Ginkgosome; Pharmacokinetics.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Cross-Over Studies
  • Double-Blind Method
  • Female
  • Ginkgo Extract
  • Ginkgo biloba*
  • Humans
  • Male
  • Plant Extracts*

Substances

  • Plant Extracts
  • Ginkgo biloba extract
  • Ginkgo Extract